Weight regain happens 4x faster after stopping GLP

• Facebook
• Twitter
• Threads
• Flipboard
• Comments
• Print
• Email
• Add Fox News on Google

Weight-loss journeys can cause social strains for GLP-1 patients, doctor says

Dr. Rocio Salas-Whalen shares how rapid GLP-1–driven weight reductions leave many individuals confronting psychological challenges that complicate relationships and social routines.

NEWYou can now listen to Fox News articles!

Discontinuing the use of GLP-1 weight-loss medications triggers weight regain more than previously thought, a new study suggested.

The research, which was published in The BMJ, found that stopping the drugs is also associated with a reversal of improvements in heart and metabolic health, including cholesterol and blood pressure.

University of Oxford researchers analyzed 37 studies published up to February 2025, involving more than 9,000 participants who had undergone an average of 39 weeks of weight-loss treatment.

OLDER AMERICANS ARE QUITTING GLP-1 WEIGHT LOSS DRUGS FOR 4 KEY REASONS

On average, patients regained about 0.9 pounds per month after stopping treatment. Researchers estimated that body weight and risk markers for diabetes and heart disease would return to pre-treatment levels in less than two years.

On average, patients regained about 0.9 pounds per month after stopping treatment. (iStock)

The analysis also revealed that the weight came back on nearly four times faster than after changing or quitting a diet or exercise regimen, no matter how many pounds had been shed.

OBESITY EXPERT REVEALS THE BEST WAY TO DECIDE IF GLP-1S ARE RIGHT FOR YOU

"The evidence suggests that despite their success in achieving initial weight loss, these drugs alone may not be sufficient for long-term weight control," the researchers commented in a press release.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The study authors acknowledged that only eight studies assessed treatment with newer GLP-1 drugs, at a maximum follow-up period of 12 months after the medication was stopped. This could serve as a limitation, although three additional methods of analysis provided similar results.

These findings question the effectiveness of GLP-1s for long-term weight loss, the researchers noted. (iStock)

In an editorial responding to the study, Dr. Qi Sun, associate professor of medicine at Brigham and Women’s Hospital and Harvard Medical School, wrote that these findings "cast doubt" on the idea that GLP-1s are a "perfect cure for obesity."

CLICK HERE FOR MORE HEALTH STORIES

"People taking GLP-1 receptor agonists should be aware of the high discontinuation rate and the consequences of cessation of medications," he said. "Healthy dietary and lifestyle practices should remain the foundation for obesity treatment and management, with medications such as GLP-1 receptor agonists used as adjuncts."

"Many of the patients who quit their GLP-1 drugs could have stayed on them with the right personalized care."

本文地址：http://www.lajxe79.cn/html/67d8799845.html%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l%20l

很赞哦!（7）

上一篇： Hộ kinh doanh vượt 500 triệu đồng vẫn phải nộp thuế VAT từ đồng đầu tiên

下一篇： Fami通周销榜：《马里奥赛车：世界》三连冠 累计销量近250万